NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is set to host a virtual investor webinar on Thursday, March 12, 2026, at 11:30 a.m. Eastern Time, as announced on February 26, 2026. The company, dedicated to revolutionizing treatment and diagnostic methods for neurological disorders, aims to provide participants with comprehensive updates regarding its current operations and future growth strategies during this session.

The webinar will cover an array of topics, including updates on NeuroOne's platform technologies and applications, as well as insights into their commercialization efforts. Following the presentation, a question-and-answer segment will allow attendees to engage directly with management, facilitating a deeper understanding of the company’s initiatives and vision.

To join the virtual event, participants can dial in using the U.S. toll-free number 888-506-0062 or the international number 973-528-0011, utilizing the participant access code 358063. It is recommended that attendees join at least five minutes in advance to ensure proper connectivity. For those unable to attend, a replay of the webinar will be accessible until March 26, 2026, via a dedicated playback number and a webcast link.

NeuroOne is known for its innovative approach to surgical care, offering a minimally invasive, high-definition electrode technology platform that includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for brain applications, and the OneRF® Trigeminal Nerve Ablation System. These products are designed to enhance patient outcomes, minimize hospital stays, and reduce overall treatment costs by integrating diagnostic and therapeutic functions.

For more information about NeuroOne’s initiatives and technologies, interested parties can visit their official website.

As NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) prepares to host its virtual investor webinar on March 12, 2026, investors should carefully consider the implications of this event, which promises to offer valuable insights into the company's strategic direction and technological advancements. NeuroOne focuses on pioneering minimally invasive surgical solutions for neurological disorders, a sector currently experiencing significant growth due to increasing incidences of neurological diseases and advancements in medical technologies.

The upcoming webinar will address NeuroOne’s corporate updates and growth strategies, crucial for understanding how the company plans to leverage its proprietary platforms. NeuroOne's FDA-cleared products, including the Evo® Cortical and sEEG Electrodes, as well as the OneRF® Ablation Systems, position the company favorably in the market, especially as healthcare increasingly shifts towards less invasive procedures that promise improved patient outcomes. Investors should pay close attention to any commentary regarding commercialization efforts and partnerships, as these will offer insight into market adoption and potential revenue streams.

Moreover, NeuroOne’s ongoing research and development initiatives into drug delivery and spinal cord stimulation represent promising avenues for future growth. Investors can glean further insights into the potential impact of these innovations on the company’s valuation and market position during the Q&A session following the corporate update.

Given the importance of the findings conveyed during this webinar, stakeholders would benefit from participating live or reviewing the playback afterward. As NeuroOne navigates this critical phase of growth, maintaining a watchful eye on the metrics discussed in the webinar will be essential for informed investment decisions. Overall, NeuroOne presents a compelling case for growth in the evolving medical technology landscape, making it a stock worth considering for those interested in the future of neurological treatments.